BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18702822)

  • 41. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM; Munro AF; Dunn JA; McConkey C; Jordan S; Twelves CJ; Cameron DA; Thomas J; Campbell FM; Rea DW; Provenzano E; Caldas C; Pharoah P; Hiller L; Earl H; Poole CJ
    Lancet Oncol; 2010 Mar; 11(3):266-74. PubMed ID: 20079691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
    Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
    Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.
    Järvinen TA; Liu ET
    Comb Chem High Throughput Screen; 2003 Aug; 6(5):455-70. PubMed ID: 12871052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
    Bartlett JM; McConkey CC; Munro AF; Desmedt C; Dunn JA; Larsimont DP; O'Malley FP; Cameron DA; Earl HM; Poole CJ; Shepherd LE; Cardoso F; Jensen MB; Caldas C; Twelves CJ; Rea DW; Ejlertsen B; Di Leo A; Pritchard KI
    J Clin Oncol; 2015 May; 33(15):1680-7. PubMed ID: 25897160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FISH Analysis of TOP2A and HER-2 Aberrations in Female Breast Carcinoma on Archived Material: Egyptian NCI Experience.
    Badawy OM; Loay I
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):216-222. PubMed ID: 28800016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
    Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
    Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
    Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
    Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
    Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
    Nielsen KV; Ejlertsen B; Møller S; Jensen MB; Balslev E; Müller S; Knoop A; Mouridsen HT
    Mol Oncol; 2012 Feb; 6(1):88-97. PubMed ID: 22153616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.
    Sparano JA; Goldstein LJ; Davidson NE; Sledge GW; Gray R
    Breast Cancer Res Treat; 2012 Jul; 134(2):751-7. PubMed ID: 22706628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
    Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
    Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
    Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.